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Introduction
In the last decades, many promising disease-modifying treatments for Alzheimer’s disease (AD)
have been proposed. However, clinical trials conducted on the treatments’ efficacy have not lead
to any important breakthroughs. There is a growing consensus that this can, at least partially, be
explained by methodological difficulties, including the inclusion of participants who are already in
the later stages of the disease progression, and the selection of outcomemeasures – such as dementia
conversion rate – which are not sensitive enough (Aisen et al., 2011).
Most of the current assessment tools have been accused to be artificial and to lack ecological
validity (Robert et al., 2013). Furthermore, test results can show variability depending on many
factors, such as the patient’s emotional state, and may therefore not always fully reflect a patient’s
capacities and the complexity of the disease, leading to delayed diagnosis (Sampaio, 2007).
Based on the Monaco CTAD expert meeting in 2012, Robert et al. (2013) highlighted that new
Information andCommunication Technologies (ICT) – such as video and audio analysis techniques,
computerized testing and actigraphy –may represent promising new tools to improve the functional
and cognitive assessment of patients with Alzheimer’s disease (AD) and related disorders [see also
Konig et al. (2014), for a recent review of studies employing ICT in this domain]. However, these new
technologies are still not widely employed in clinical trials for assessment purposes. In November
2014, the association Innovation Alzheimer organized a workshop with stakeholders in the field
(e.g., psychiatrist, neurologists, geriatricians, psychologists, researchers, engineers, and patients)
with the aim of gathering recommendations for the use of ICT in the different stages of clinical
trials. These recommendations are available online on the website of the Association Innovation
Alzheimer1.
Based on these recommendations, in the present opinion paper, we will highlight how ICT may
be employed in clinical trials involving patients with AD and related disorders to improve patient’s
assessment and the admissibility to participate in clinical trials.
1http://www.innovation-alzheimer.fr/homepage/
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The Current Use of ICT in Clinical Trials
Information and Communication Technologies is now widely
employed in several stages of clinical trials. For instance, phar-
maceutical companies and Contract Research Organizations rou-
tinely adopt E-trainings for investigators. Patients’ recruitment
can take advantage of the wide employ of Electronic Health
Records storing health-related data (Hsiao and Hing, 2014), and
E-recruitment methods employing social media and the Internet
are also starting to emerge. Similarly, data entry is now facili-
tated by electronic Case Report Forms, employed in almost the
totality of the clinical trials leaded by pharmaceutical companies
(Kuchinke et al., 2010). However, ICT is still not consistently used
in clinical trials at the assessment stage.
ClinicalTrials.gov – a registry and results database of pub-
licly and privately supported clinical studies of human partici-
pants conducted around the world – contains at present (January
2015) more than 2500 clinical trials involving participants with
mild cognitive impairment (MCI), AD, or other dementia types.
We performed a keyword-based2 search on these trials focusing
on automated audio and video analysis techniques, actigraphy,
and computerized testing. Only 16 pharmaceutical trials employ-
ing ICT for assessment purposes were retrieved: 6 employing
accelerometers and 10 employing computerized testing. No study
employing automated audio or video analysis techniques was
found. While it is certainly possible that these numbers represent
an underestimate, they suggest that more work should be done
to bring the clinical domain closer to the frontiers of the clinical
research.
2Keywords : “audio analysis”, “speech analysis”, “audio recording”, “voice recording”,
“voice recognition”, “video recording”, “video recognition”, “video analysis”, “3D
recognition”, “accelerometer”, “actigraph” “actigraphy”, “motion sensor”, “comput-
erized test/testing”, “computer test/testing”
ICT for Assessment in Clinical Research
The design of ICT solutions for the health domain is a complex
process, which requires the close collaboration of different stake-
holders (see Figure 1). Recent evidence suggests that ICT can
play a crucial role in the assessment of AD and related disorders,
both in terms of providing additional information for an earlier
and more accurate diagnosis, and in terms of monitoring of the
disease progression (Robert et al., 2013). For instance, it has been
shown that automatic speech analysis techniques – analyses of
verbal communication through computerized speech recognition
interfaces – can represent a non-invasive and cheap method to
gather information about verbal communication impairments,
which are very common in patients with MCI and in the early
stages of AD (Satt et al., 2013). These techniques are useful for
automating the analysis of clinical and neuropsychological tests
employed to assess linguistic abilities (such as verbal fluency and
sentence repetition tests). But even more importantly, they can
provide additional information that cannot be gathered in a clini-
cal setting, such as utterance duration, filler typology, and analysis
of voiced and voiceless segments. Recently, we showed that the
vocal markers extracted from speech signal processing techniques
differed significantly among healthy elderly participants, MCI,
and early ADpatients with accuracy higher than 80% (König et al.,
2015a,b).
Similar observations apply to automatic video analysis tech-
niques (Romdhane et al., 2012; Sacco et al., 2012; Konig et al.,
2015c). These techniques have proven to be useful for fall
detection and to improve home safety (Robinovitch et al., 2013),
but recently they started to be adopted also for assessment pur-
poses. For instance, in the FP7 project Dem@Care3 video analysis
techniques are employed to provide objective measures to assess
3www.demcare.eu
FIGURE 1 | Flowchart representing the different stakeholders (A) and
the main steps involved in the design of ICT solutions for the health
domain (B). (B) User’s needs: finding and screening the patient’s needs with
patients, caregivers, and clinicians. Co-design: generating ideas and
selecting viable ICT solutions with patients, caregivers, clinicians, and ICT
engineers. Prototype development: developing a first ICT prototype with
clinicians, ICT engineers, and businessmen. Pilot and ICT trial: initial tests on
the usability/feasibility of the ICT solution, followed by prototype
modifications. Clinical trial: study on a larger, well-defined patient’s
population in order to test the efficacy of the ICT solution in short and
medium terms. Labeling, authorizations, marketing: leaded by ICT/business
stakeholders with the help of clinicians, patients, and caregivers.
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functional impairments in activities of daily living in elderly peo-
ple and patients withMCI andAD. In the classical clinical settings,
autonomy in activities such as taking medications, or handling
finances are assessed through self-reports and informant-based
questionnaires, which do not offer accurate, reproducible, objec-
tive, and ecological measures of functional performance. Using
non-invasive 2D video recordings combined with video signal
analysis, Konig et al. (2015c) showed that activities of daily living
can be accurately detected and recognized by automated activity
recognition algorithms, as suggested by results highly consis-
tent with the clinician’s evaluation. Furthermore, video analysis
allowed obtaining finer-grade measures, such as the time spent
on each activity, which could not be captured in the classical
clinical evaluation. Siraly et al. (2015) investigated if early signs
of cognitive decline could be monitored by computer memory
gameswith the results that healthy elderly subjects achieving lower
scores in the memory game have increased level of atrophy in the
temporal brain structures and showed a decreased performance
in the Paired Associates Learning (PAL) test. Thus, computer
games may be useful tools in early screening for cognitive decline.
Similarly, online questionnaires tapping risk and protective fac-
tors in different health domains (e.g., diet, physical and cogni-
tive activity, social engagement), such as those developed in the
FP7 project InMINDD4, are starting to be employed to assess
brain health and to screen for participants at risk of developing
dementia.
A final example is represented by actigraphy, which is
frequently used to monitor motor activity and rest-activity
rhythms (Hatfield et al., 2004), and it has been proposed as
an observer-independent evaluation method in different dis-
orders, including dementia (Yakhia et al., 2014). Specifically,
its utility as an assessment tool in AD and related disorders
has been proven to assess neuropsychiatric symptoms such as
agitation (Nagels et al., 2006; Mahlberg and Walther, 2007),
depression (Volkers et al., 2003), and apathy (David et al.,
2012). See Konig et al. (2014) for recent reviews on the use
of actigraphy for assessment in patients with AD and related
disorders.
Why Should ICT Be Employed More
Consistently in Clinical Trials?
As detailed above, ICT-based techniques may represent
non-invasive, objective, and inexpensive solutions to detect
early cognitive and functional decline in patients with AD.
Clinical interventional trials may take advantage of these
solutions in several ways. First, ICT may contribute to determine
the admissibility of participation in clinical trials at earlier
stages of the disease, when treatment is supposed to be more
effective. Patient’s performance scores on one assessment may
fluctuate as a function of daily rhythms, fatigue, emotion, stress,
and many other state-dependent factors. Due to this variance,
certain difficulties present in the earliest stages of AD and related
disorders may be undetectable during the classical assessment.
4http://www.inmindd.eu/
ICT may be of great interest in this respect, because they enable
the patients’ performance to be captured and accurately evaluated
in real time and real life situations, even at the patient’s home
(Robert et al., 2013). Second, ICT may help in providing a more
timely conversion diagnosis, thus improving the sensitivity of
outcome measures based on conversion rate as end-point of
the intervention. Similarly, by allowing easy and non-invasive
continuous monitoring of the patient over time, ICT can help
assessing subtle changes in behavioral, cognitive, and functional
patterns, and thus contribute to the definition of outcome
measures finer than dementia progression or neuropsychological
test scores. Finally, ICT may provide an interesting solution for
remote assessment and follow-up. One of the challenges faced by
big cohort clinical studies is that there is a consistent drop-out
rate, at least partially due to the fact that patients need to go
to a clinic for the assessments and follow-ups. ICT solutions
combined with safe data transfer methods may reduce drastically
the number of required visits, thus reducing the drop-out rate
and the costs/time associated with the clinical trial.
An interesting example of how ICT could be employed in clin-
ical trials is represented by the assessment of agitation. Agitation
represents one of the most frequent neuropsychiatric symptoms
in patients with dementia, and one of the most challenging symp-
toms to manage for primary caregivers (Okura and Langa, 2011).
Following the Agitation Definition Work Group provisional con-
sensus definition (Cummings et al., 2015), agitation in patients
with cognitive disorders is defined by (A) the presence of criteria
for a cognitive impairment or dementia syndrome, and (B) the
presence at least one of the following behaviors associated with
observed or inferred evidence of emotional distress for a mini-
mumof 2weeks, which represent a change from the patient’s usual
behavior: (a) excessive motor activity; (b) verbal aggression; (c)
physical aggression.
As for cognition, pharmacological solutions for agitation have
given so far disappointing results (Soto et al., 2014). However,
recently a new promising treatment has been released and tested,
and showed preliminary efficacy evidence in larger cohort trials
(Cummings et al., 2014; Siffert, 2014). ICT could play a key
role in assessing agitation in patients with AD, and to test the
new treatment efficacy. For instance, accelerometers could be
employed to measure objectively the presence of abnormal motor
activity. Speech analyses that extract automatically vocal features
of recorded speech could be employed to assess verbal aggression
in a more subtle and objective way. Finally, automated video anal-
ysis and activity-recognition techniques may be useful to quantify
the appearance of certain activities and movement sequences that
underline physical aggression.
Conclusion and Future Research
Directions
In order to progress in the validation of the treatments for AD,
better outcome measures for cognitive and functional changes
are acutely needed in the earliest stages of the pathology (Snyder
et al., 2014). The clinical assessment of cognitive and functional
changes in AD has traditionally relied on cognitive screening tests
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that are not always sensitive to the earliest cognitive, functional,
and behavioral changes important to detect for effective preven-
tive interventions (Snyder et al., 2014), are possibly subjected to
variations in the clinical interpretation, and are not always good
predictor of the progression from MCI to AD (Schmand et al.,
2012). Furthermore, current diagnostic measures can be inva-
sive (CSF analyses), expensive (neuroimaging), time-consuming
(neuropsychological assessment), and are often available only in
specialized clinics, which lead to reduced accessibility as frontline
screening tool for AD and related disorders (Laske et al., 2014).
Therefore, we face an increasing need for additional population-
based screening and follow-up instruments with simpler and
timelier adapted, non-invasive, and cost-effective tools allowing
early identification of subjects in preclinical stages of AD.
Here, we highlighted how new tools involving ICT may rep-
resent an optimal solution to most of these challenges. However,
in order to successfully integrate ICT measurements into clinical
trials, some work has still to be done (Robert et al., 2013, 2014).
Specifically, the use of such technologies should be validated in
larger cohorts to demonstrate their clinical meaningfulness by
correlating with available clinical diagnostics and biomarkers and
thus receive recognition in the clinical scientific and medical
world. Importantly, in addition, the use of ICT in clinical trials
needs to be validated by Health authorities and policy makers. On
the technological side, work in terms of system development and
sensors integration has to be carried out to allow a reliable and
complete assessment of a patient by merging information coming
from different sensors into easily understandable feedback. The
immediate and accurate visualization of the recorded data is of
great importance to facilitate an easy use in clinical practice and
to provide feedback to patients and their caregivers.
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